KRT14 and metabolic syndrome: Compared to the vehicle-treated K14-VEGF-A-transgenic group, CDCA effectively improved blood dyslipidemia in K14-VEGF-A-transgenic mice by reducing the concentrations of serum LDL (Figure 6B), and the CDCA-treated group showed a significant improvement in the fasting blood glucose (Figure 6C).